These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life. Kamath BM; Goldstein A; Howard R; Garner W; Vig P; Marden JR; Billmyer E; Anderson A; Kirson N; Jacquemin E; Gonzales E J Pediatr; 2023 Jan; 252():68-75.e5. PubMed ID: 36096175 [TBL] [Abstract][Full Text] [Related]
9. Maralixibat: First Approval. Shirley M Drugs; 2022 Jan; 82(1):71-76. PubMed ID: 34813049 [TBL] [Abstract][Full Text] [Related]
10. Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome. Shneider BL; Spino C; Kamath BM; Magee JC; Bass LM; Setchell KD; Miethke A; Molleston JP; Mack CL; Squires RH; Murray KF; Loomes KM; Rosenthal P; Karpen SJ; Leung DH; Guthery SL; Thomas D; Sherker AH; Sokol RJ; Hepatol Commun; 2018 Oct; 2(10):1184-1198. PubMed ID: 30288474 [TBL] [Abstract][Full Text] [Related]
11. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Kamath BM; Stein P; Houwen RHJ; Verkade HJ Liver Int; 2020 Aug; 40(8):1812-1822. PubMed ID: 32492754 [TBL] [Abstract][Full Text] [Related]
12. Ileal Bile Acid Transporter Blockers for Cholestatic Liver Disease in Pediatric Patients with Alagille Syndrome: A Systematic Review and Meta-Analysis. Muntaha HST; Munir M; Sajid SH; Sarfraz Z; Sarfraz A; Robles-Velasco K; Sarfraz M; Felix M; Cherrez-Ojeda I J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556142 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of liver transplantation for Alagille syndrome after Kasai portoenterostomy: Alagille Syndrome with agenesis of extrahepatic bile ducts at porta hepatis. Gunadi ; Kaneshiro M; Okamoto T; Sonoda M; Ogawa E; Okajima H; Uemoto S J Pediatr Surg; 2019 Nov; 54(11):2387-2391. PubMed ID: 31104835 [TBL] [Abstract][Full Text] [Related]
14. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. Baumann U; Sturm E; Lacaille F; Gonzalès E; Arnell H; Fischler B; Jørgensen MH; Thompson RJ; Mattsson JP; Ekelund M; Lindström E; Gillberg PG; Torfgård K; Soni PN Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101751. PubMed ID: 34182185 [TBL] [Abstract][Full Text] [Related]
15. Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency. Zhao X; Zhang W; Vig P; Kostrub C; Setchell KDR Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295854 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study. Bowlus CL; Eksteen B; Cheung AC; Thorburn D; Moylan CA; Pockros PJ; Forman LM; Dorenbaum A; Hirschfield GM; Kennedy C; Jaecklin T; McKibben A; Chien E; Baek M; Vig P; Levy C Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37184523 [TBL] [Abstract][Full Text] [Related]
17. Exploring odevixibat's efficacy in alagille syndrome: insights from recent clinical trials and IBAT inhibitor experiences. Jarasvaraparn C; Rodrigo M; Hartley C; Karnsakul W Expert Opin Pharmacother; 2024 Aug; 25(12):1647-1655. PubMed ID: 39155775 [TBL] [Abstract][Full Text] [Related]
18. Partial external biliary diversion in children with progressive familial intrahepatic cholestasis and Alagille disease. Yang H; Porte RJ; Verkade HJ; De Langen ZJ; Hulscher JB J Pediatr Gastroenterol Nutr; 2009 Aug; 49(2):216-21. PubMed ID: 19561545 [TBL] [Abstract][Full Text] [Related]
19. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Emerick KM; Whitington PF Hepatology; 2002 Jun; 35(6):1501-6. PubMed ID: 12029636 [TBL] [Abstract][Full Text] [Related]
20. Use of funded multicenter prospective longitudinal databases to inform clinical trials in rare diseases-Examination of cholestatic liver disease in Alagille syndrome. Shneider BL; Kamath BM; Magee JC; Goodrich NP; Loomes KM; Ye W; Spino C; Alonso EM; Molleston JP; Bezerra JA; Wang KS; Karpen SJ; Horslen SP; Guthery SL; Rosenthal P; Squires RH; Sokol RJ; Hepatol Commun; 2022 Aug; 6(8):1910-1921. PubMed ID: 35506349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]